157 related articles for article (PubMed ID: 32747623)
1. Preclinical support for the therapeutic potential of zolmitriptan as a treatment for cocaine use disorders.
Garcia R; Le T; Scott SN; Charmchi D; Sprout JML; Pentkowski NS; Neisewander JL
Transl Psychiatry; 2020 Aug; 10(1):266. PubMed ID: 32747623
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Evidence That 5-HT1B Receptor Agonists Show Promise as Medications for Psychostimulant Use Disorders.
Garcia R; Cotter AR; Leslie K; Olive MF; Neisewander JL
Int J Neuropsychopharmacol; 2017 Aug; 20(8):644-653. PubMed ID: 28444326
[TBL] [Abstract][Full Text] [Related]
3. 5-HT
Scott SN; Garcia R; Powell GL; Doyle SM; Ruscitti B; Le T; Esquer A; Blattner KM; Blass BE; Neisewander JL
J Psychopharmacol; 2021 Oct; 35(10):1216-1225. PubMed ID: 34049460
[TBL] [Abstract][Full Text] [Related]
4. Zolmitriptan--a 5-HT1B/D agonist, alcohol, and aggression in mice.
de Almeida RM; Nikulina EM; Faccidomo S; Fish EW; Miczek KA
Psychopharmacology (Berl); 2001 Sep; 157(2):131-41. PubMed ID: 11594437
[TBL] [Abstract][Full Text] [Related]
5. Review of zolmitriptan and its clinical applications in migraine.
Dowson AJ; Charlesworth B
Expert Opin Pharmacother; 2002 Jul; 3(7):993-1005. PubMed ID: 12083998
[TBL] [Abstract][Full Text] [Related]
6. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan).
Martin GR; Robertson AD; MacLennan SJ; Prentice DJ; Barrett VJ; Buckingham J; Honey AC; Giles H; Moncada S
Br J Pharmacol; 1997 May; 121(2):157-64. PubMed ID: 9154322
[TBL] [Abstract][Full Text] [Related]
7. 5-HT1B receptors, alpha2A/2C- and, to a lesser extent, alpha1-adrenoceptors mediate the external carotid vasoconstriction to ergotamine in vagosympathectomised dogs.
Valdivia LF; Centurión D; Arulmani U; Saxena PR; Villalón CM
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jul; 370(1):46-53. PubMed ID: 15224175
[TBL] [Abstract][Full Text] [Related]
8. Zolmitriptan stimulates a Ca(2+)-dependent K(+) current in C6 glioma cells stably expressing recombinant human 5-HT(1B) receptors.
Le Grand B; Panissié A; Perez M; Pauwels PJ; John GW
Eur J Pharmacol; 2000 Jun; 397(2-3):297-302. PubMed ID: 10844127
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques.
Nilsson T; Longmore J; Shaw D; Pantev E; Bard JA; Branchek T; Edvinsson L
Eur J Pharmacol; 1999 May; 372(1):49-56. PubMed ID: 10374714
[TBL] [Abstract][Full Text] [Related]
10. Effects of serotonin 5-HT1B receptor ligands on the cocaine- and food-maintained self-administration in rats.
Przegaliński E; Gołda A; Frankowska M; Zaniewska M; Filip M
Eur J Pharmacol; 2007 Mar; 559(2-3):165-72. PubMed ID: 17291490
[TBL] [Abstract][Full Text] [Related]
11. Cranial vascular effects of zolmitriptan, a centrally active 5-HT1B/1D receptor partial agonist for the acute treatment of migraine.
MacLennan SJ; Cambridge D; Whiting MV; Marston C; Martin GR
Eur J Pharmacol; 1998 Nov; 361(2-3):191-7. PubMed ID: 9865508
[TBL] [Abstract][Full Text] [Related]
12. A PET study with [11C]AZ10419369 to determine brain 5-HT1B receptor occupancy of zolmitriptan in healthy male volunteers.
Varnäs K; Jučaite A; McCarthy DJ; Stenkrona P; Nord M; Halldin C; Farde L; Kanes S
Cephalalgia; 2013 Jul; 33(10):853-60. PubMed ID: 23430984
[TBL] [Abstract][Full Text] [Related]
13. Zolmitriptan-induced growth hormone release in humans: mediation by 5-HT1D receptors?
Whale R; Bhagwagar Z; Cowen PJ
Psychopharmacology (Berl); 1999 Jul; 145(2):223-6. PubMed ID: 10463324
[TBL] [Abstract][Full Text] [Related]
14. [Mechanism of action of zolmitriptan].
Pascual J
Neurologia; 1998 Oct; 13 Suppl 2():9-15. PubMed ID: 9859690
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of the serotonin receptor agonist, zolmitriptan.
Peterlin BL; Rapoport AM
Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):899-911. PubMed ID: 18028032
[TBL] [Abstract][Full Text] [Related]
16. Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain.
Johnson DE; Rollema H; Schmidt AW; McHarg AD
Eur J Pharmacol; 2001 Aug; 425(3):203-10. PubMed ID: 11513839
[TBL] [Abstract][Full Text] [Related]
17. Serotonin 5HT1B/1D receptor agonists abolish NMDA receptor-evoked enhancement of nitric oxide synthase activity and cGMP concentration in brain cortex slices.
Stepień A; Chalimoniuk M; Strosznajder J
Cephalalgia; 1999 Dec; 19(10):859-65. PubMed ID: 10668104
[TBL] [Abstract][Full Text] [Related]
18. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. The International 311C90 Long-term Study Group.
Headache; 1998 Mar; 38(3):173-83. PubMed ID: 9563207
[TBL] [Abstract][Full Text] [Related]
19. The effects of 5-HT1A, 5-HT1B and 5-HT1D receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats.
Cumberbatch MJ; Hill RG; Hargreaves RJ
Eur J Pharmacol; 1998 Nov; 362(1):43-6. PubMed ID: 9865528
[TBL] [Abstract][Full Text] [Related]
20. Zolmitriptan: a review of its use in migraine.
Spencer CM; Gunasekara NS; Hills C
Drugs; 1999 Aug; 58(2):347-74. PubMed ID: 10473025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
